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Sarcopenia, the decline in muscle mass and functionality during aging, might arise from age-associated endocrine 
dysfunction. Ghrelin is a hormone circulating in both acylated (AG) and unacylated (UnAG) forms with anti-
atrophic activity on skeletal muscle. Here, we show that not only lifelong overexpression of UnAG (Tg) in mice, but 
also the deletion of ghrelin gene (Ghrl KO) attenuated the age-associated muscle atrophy and functionality 
decline, as well as systemic inflammation. Yet, the aging of Tg and Ghrl KO mice occurs with different dynamics: 
while old Tg mice seem to preserve the characteristics of young animals, Ghrl KO mice features deteriorate with 
aging. However, young Ghrl KO mice show more favorable traits compared to WT animals that result, on the 
whole, in better performances in aged Ghrl KO animals. Treatment with pharmacological doses of UnAG improved 
muscle performance in old mice without modifying the feeding behavior, body weight, and adipose tissue mass. 
The antiatrophic effect on muscle mass did not correlate with modifications of protein catabolism. However, 
UnAG treatment induced a strong shift towards oxidative metabolism in muscle. Altogether, these data confirmed 
and expanded some of the previously reported findings and advocate for the design of UnAG analogs to treat 
sarcopenia. 
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INTRODUCTION 
 
Sarcopenia, the decline in muscle mass and functionality 
during aging, often results in poor balance, higher risk of 
falls, fractures, immobilization, loss of independence, 
and increased morbidity and mortality, thus representing 
a major health issue in elder individuals [1–3]. 
 
Muscle wasting follows the general decline in trophic 
hormones or in their ability of eliciting their standard 
cellular response (“resistance”) and the establishment of 
a chronic mild inflammatory status characteristic of 
aging [4]. 
 
Ghrelin is a gastric hormone peptide circulating in both 
acylated (AG) and unacylated (UnAG) forms. AG is the 
endogenous ligand of the growth hormone secretagogue 
receptor (GHSR-1a), and it is involved in metabolic 
regulation and energetic balance through induction of 
appetite, food intake, and adiposity [5, 6]. UnAG does 
not induce GH release and has no direct effects on food 
intake, but it shares with AG several biological 
activities both in vitro and in vivo independently of the 
expression of AG receptor. Indeed, in vivo, both AG 
and UnAG protect Ghsr KO mice from fasting- and 
denervation-induced skeletal muscle atrophy, thus 
proving the existence of a yet unidentified receptor that 
mediates the common AG and UnAG biological 
activities [7]. Consistently, both AG and UnAG have 
direct biological activities in vitro on skeletal muscle, 
including promotion of myoblast differentiation [8], 
protection from atrophy [7], and stimulation of 
mitochondrial respiration capacity [9]. In addition, 
UnAG boosts muscle satellite cell activity, activates 
autophagy and mitophagy, and stimulates insulin 
sensitivity, thus promoting muscle regeneration or 
preventing skeletal mass loss in different disease 
models, including hindlimb ischemia, high-fat diet-
induced diabetes, and chronic kidney disease [10–14]. 
Similarly to other hormones, in humans, ghrelin levels 
decrease with aging [15], and the hypoghrelinemic state 
in the elderly could participate in the establishment of 
sarcopenia by facilitating the progression of muscle 
atrophy and limiting skeletal muscle regeneration 
capability. In mice, on the contrary, it was reported an 
increase in circulating levels of AG during aging [16], a 
phenomenon that has been proposed to represent a 
compensatory mechanism to a decline in receptor or 
post-receptor functions [17]. 
 
The role of ghrelin during aging has been recently 
investigated through the analysis of ghrelin knockout 
mice, and, surprisingly, it has emerged that ghrelin 
deletion prevents age-associated development of obesity 
and attenuates the decline in muscle strength and 
endurance seen with aging [18]. Nevertheless, the 
treatment of old WT mice with AG partially restored 
muscle performance while increasing food intake and 
body weight, especially fat mass [18]. Since an increase 
in obesity, a side effect of AG, in elderly subjects could 
worsen sarcopenia [19], inducing insulin resistance and 
diabetes [20], and mediating age-associated adipose 
tissue inflammation [21], here we explored the 
potentiality of UnAG in protecting from age-associated 
muscle wasting avoiding the potential adverse 
metabolic effects of AG. In addition, we expanded the 
previously reported characterization of ghrelin knockout 
mice during aging, especially focusing on the 




Changes of AG and UnAG level changes in WT mice 
during aging 
 
Beside the already demonstrated age-related increase  
of AG [16], in WT mice, we also observed a rise in  




Figure 1. Increase of AG and UnAG plasmatic levels during aging in WT mice. Plasmatic levels of AG (A) and UnAG (B) in 3-, 12-, and 
24-month-old mice determined by EIA; 3-month-old mice: N = 5, 12-month-old mice N = 8, 24-month-old mice N = 6. Data in bar graph are 
presented as mean ± SEM. *p<0.05 and **p<0.01 vs. 3-month-old mice. 
 
www.aging-us.com 13941 AGING 
phenomenon that could represent a compensatory 
mechanism to age-induced ghrelin resistance [17]. It has 
been proposed that age-related ghrelin resistance could 
be due to a decline in ghrelin-elicited signaling or to 
changes in the levels of its receptor. However, the levels 
of AG receptor in skeletal muscle were no detectable 
neither in young nor in old WT animals (data not 
shown) and, being the receptor mediating the common 
AG/UnAG antiatrophic activity [7] still unknown, its 
expression cannot be assessed. Therefore, the 
relationship between AG/UnAG levels and their 
receptors still remains to be elucidated. 
 
Body weight, body composition, and food intake in 
young, adult, middle aged, and old WT, Tg, and Ghrl 
KO mice 
 
To address whether ghrelin levels during aging affect 
sarcopenia development, we examined young (3-month-
old), adult (6-month-old), middle-aged (12-month-old), 
and old (24-month-old) Myh6/Ghrl transgenic mice 
characterized by high levels of circulating UnAG, up to 
100 times more than WT animals (Tg; [7, 13]), their 
WT littermates, and ghrelin knockout (Ghrl KO; [22]) 
mice, lacking all the gene-derived peptides. 
 
We observed a general increase in body weight and 
BMI for all genotypes during aging up to 12 months, 
with a remarkable drop at 24 months of age (Figure 2A 
and Table 1). A similar trend was observed also for 
epididymal fat and skeletal muscles (Figure 2B, 2C and 
Table 1), suggesting the establishment of progressive 
sarcopenia starting from 12 months in all genotypes. 
 
Other organs, such as the heart, liver, and spleen, on the 
contrary, steadily increased during aging (Table 1). 
Daily food intake increased in adult mice compared to 
young ones in all genotypes. Afterwards, in WT and  
Tg, daily food intake decreased with aging. On the 
contrary, Ghrl KO mice exhibited a higher food intake 
at 3 months of age that remained stable during aging 
(Table 1). 
 
Muscle and cognitive performance in young and old 
WT, Tg, and Ghrl KO mice 
 
To assess the effect of altered ghrelin levels during 
aging on muscle functionality, we measured the 
performances of young and old WT, Tg, and Ghrl KO 
mice using the hanging wire test. This test allows 
determining muscle function and coordination by 
counting the times a mouse falls or reaches one of the 
sides of the wire and the tension that the animal 
develops for maintaining itself on the wire, against 
gravity, by measuring the longest suspension time. In 
general, mice from all genotypes showed a decrease in 
muscle performance during aging. However, 
surprisingly, Ghrl KO mice outclassed both WT and Tg 
mice, at both ages, in the “falls and reach” score, as well 
in the holding impulse (Figure 3A, 3B). On the other 
hand, Tg mice performances were barely 
distinguishable from those of their WT littermates, both 
in young and old animals. 
 
Since the score on the hanging wire test could be 
affected by cognitive performance and stress 
susceptibility, we assessed if cognitive capability and 
anxiety/depression of mice were different among the 
strains. Young Ghrl KO mice undergoing the object 
recognition test obtained a higher discrimination index 
than young WT and Tg (Figure 3C). However, at 24 
months of age, while no significant changes were 
observed in the discrimination index of WT and Tg 
mice, that of Ghrl KO mice dropped to a level similar to 
those of WT mice. The tail suspension test, with the 
time spent immobile representing a measure of anguish, 
showed no differences in the immobility time of young 
mice (Figure 3D). During aging, both WT and Tg mice 
had a propensity to develop depression-like behaviors, 
while Ghrl KO mice showed substantial preservation of 
the immobility time during aging. 
 
Skeletal muscle atrophy during aging in WT, Tg, 
and Ghrl KO mice 
 
Despite the lack of significant differences in the weight 
of muscles among the three genotypes and the general 
decrease in muscle mass in aged mice (Figure 2C and 
Table 1), a closer examination of muscles revealed 
differences in the expression of Atrogin-1 (Fbxo32), a 
marker and a mediator of muscle atrophy, during aging 
[23]. The age-dependent increase of Atrogin-1 mRNA 
expressions was remarkable in gastrocnemii of WT and 
Tg mice and was milder in Ghrl KO mice (Figure 4A), 
although it should be considered that Atrogin-1 mRNA 
levels were basally lower in young Ghrl KO mice 
compared to the other genotypes. This was also true in 
tibialis anterior (TA) muscles, where Atrogin-1 was 
significantly increased during aging only in Ghrl KO 
mice, reaching the values of young WT and Tg animals. 
Conversely, the increase of Atrogin-1 during aging was 
not significant in WT and absent in Tg animals. The 
mRNA expression of other markers of autophagic-
mediated catabolism, such as cathepsin-L and Bnip-3, 
showed a general tendency to increase with aging in all 
genotypes (Figure 4B, 4C), although the increase in 
cathepsin-L was significant only in WT and Tg mice. In 
the aged groups, cathepsin-L gene expression in both 
Tg and Ghrl KO mice was reduced compared to the WT 
animals, while Bnip-3 levels significantly decreased 
only in Tg mice. On the contrary, the expression of the 
anabolic marker IGF1 showed the general tendency to 
 




Figure 2. Body mass composition in young and old WT, Tg, and Ghrl KO mice. (A) Total body weight in 3-month old (young), 6-
month old (adult), 12-month old (middle aged), and 24-month old (old) mice. (B) Epidydimal fat mass normalized to nose-to-anus length 
(NAL) and (C) gastrocnemius weight normalized to the tibial length (TL). Young mice: WT = 6, Tg = 7, Ghrl KO = 5; adult mice: WT = 7, Tg 
= 4, Ghrl KO = 5; middle aged: WT = 5, Tg = 6, Ghrl KO = 9; old mice: WT= 13, Tg= 14, Ghrl KO = 11. Data in bar graphs are presented as 
mean ± SEM. For each box plot, the lower and up boundaries denote the 25th and the 75th percentile of each data set, respectively, 
the horizontal line represents the median, and the whiskers represent the min and max of values. *p<0.05 and **p<0.01 vs. young  
mice; £p<0.05 and ££p<0.01 vs. adult mice; #p<0.05 and ##p<0.01 vs. middle aged mice; $p<0.05 and $$p<0.01 Tg and Ghrl KO vs. WT. 
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6 months  
(adult) 
12 months  
(middle aged) 
24 months  
(old) 
WT 3.34±0.18 3.88±0.08* 3.97±0.07** 3.88±0.11** 
Tg 3.30±0.12 3.81±0.14* 4.16±0.21** 3.71±0.07**,# 
KO 3.77±0.16 3.61±0.12 4.75±0.14**,$$,££ 3.68±0.09## 
WT 90.25±0.35 95.26±1.26** 95.68±1.42** 90.66±1.23££,# 
Tg 91.07±1.49 93.87±1.75 95.76±1.01* 89.56±1.33## 
KO 85.11±0.76$$ 96.52±1.74** 97.96±1.57** 93.06±0.89**,# 
WT 19.84 ± 0.09 20.47 ± 0.24 20.48 ± 0.13** 20.49 ± 0.17** 
Tg 19.85 ± 0.11 20.50 ± 0.18** 20.70 ± 0.11**,$$ 20.07 ± 0.10**,$$,£ 
KO 19.82 ± 0.09$ 20.10 ± 0.07* 20.27 ± 0.18 20.70 ± 0.32**,££ 
WT 2.38±0.02 2.54±0.07 2.56±0.01** 2.28±0.03££,## 
Tg 2.52±0.04$ 2.5±0.02 2.49±0.09 2.23±0.04**,££,# 
KO 2.65±0.14 2.95±0.08*,$$ 2.81±0.04$$ 2.38±0.06££,## 
WT 10.1±0.36 11.74±0.38** 10.79±0.16£ 7.98±0.25**,££,## 
Tg 10.20±0.45 10.87±0.2 10.34±0.42 7.97±0.12**,££,## 
KO 11.28±0.57 12.36±0.42 11.64±0.08$$ 8.50±0.36**,££,## 
WT 0.56±0.02 0.58±0.02 0.56±0.02 0.48±0.01**,££,## 
Tg 0.51±0.03 0.51±0.01$$ 0.58±0.01**,££ 0.48±0.01## 
KO 0.55±0.03 0.61±0.03 0.61±0.01* 0.47±0.02*,££,## 
WT 0.45±0.02 0.46±0.03 0.48±0.01 0.38±0.01**,££,## 
Tg 0.46±0.01$$ 0.47±0.03 0.46±0.02 0.36±0.01**,££,## 
KO 0.43±0.02$$ 0.49±0.01** 0.56±0.02**,££ 0.36±0.02**,$$,££,## 
WT 1.34±0.04 1.62±0.07** 1.56±0.09** 2.00±0.10**,££,# 
Tg 1.40±0.08 1.35±0.03$$ 1.47±0.04 2.14±0.11**,££,## 
KO 1.38±0.14 1.37±0.02$$ 1.40±0.04$$ 1.92±0.11**,££,## 
WT 14.44±0.63 15.75±1.14 17.31±0.71** 19.44±0.52**,££,# 
Tg 15.64±0.48 15.14±0.77 18.21±1.35 20.55±0.64**,££,# 
KO 14.64±0.81 15.55±0.66 18.55±1.2* 18.13±0.94** 
WT 0.81±0.04 1.07±0.10* 0.91±0.05*,££ 1.91±0.27*,£ 
Tg 0.84±0.04$$ 0.89±0.05 0.84±0.02 1.67±0.11**,££,## 
KO 0.83±0.05$$ 0.84±0.04 1.04±0.06*,$$,££ 1.29±0.14*,£ 
WT 4.11±0.11 4.56±0.11** 4.23±0.10£ 4.18±0.23 
Tg 3.96±0.11 4.78±0.04* 4.21±0.25£ 4.39±0.21££ 
KO 4.33±0.23$ 4.26±0.19 4.33±0.17 4.21±0.14 
Young (WT = 6, Tg = 7, Ghrl KO = 5), adult (WT = 7, Tg = 4, Ghrl KO = 5), middle aged (WT = 5, Tg = 6, Ghrl KO = 9), old (WT = 
13, Tg = 14, Ghrl KO = 11) mice were sacrificed and measurements of the indicated parameters were carried out as described 
in Materials and Methods. Muscle mass and tibial length values were calculated as the mean of right and left hindlimbs. 
Values are the means ± SEM; *p<0.05 and **p<0.01 vs. young mice; £p<0.05 and ££p<0.01 vs. adult mice; #p<0.05 and 
##p<0.01 vs. middle aged mice; $p<0.05 and $$p<0.01 Tg and Ghrl KO vs. WT. 
 
decrease with aging in Tg and Ghrl KO mice, although 
the reduction was significant only in the former (Figure 
4D). Nevertheless, in old animals, Ghrl KO mice 
displayed a statistically significant lower expression of 
IGF1 compared to WT mice. Analyzing the fiber cross-
sectional area distributions of gastrocnemius (GAS) 
muscles from young adult and old WT mice, it was 
evident a clear shift toward smaller areas in the latter 
(Supplementary Figure 1). Since the muscles of young 
Tg and KO mice, in unstimulated conditions, do not 
differ from those of WT animals [13, 22], the shift 
towards larger areas in old Tg and Ghrl KO muscles 
compared to old WT muscles (Figure 4E) indicates that 
both high levels of circulating UnAG and the lack of 
ghrelin peptides protect against muscle mass loss during 
aging. 
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Muscle fiber types and metabolism in old WT, Tg, 
and Ghrl KO mice 
 
Muscles are more susceptible/resistant to atrophy also 
depending on their fiber type composition, being 
glycolytic fibers more prone to undergo mass loss 
compared to the oxidative ones [24]; therefore, we 
assessed if high levels of UnAG or the lack of ghrelin 
peptides could affect muscle metabolism. Succinate-
dehydrogenase (SDH) staining revealed that oxidative 
ability, i.e., the activity of complex II of the electron 
transport chain, decreases with aging both in WT and 
Ghrl KO mice, whereas it was maintained in Tg (Figure 
5A), suggesting that UnAG stimulates an oxidative 
metabolism, counteracting the age-associated shift from 
oxidative to glycolytic metabolism. 
 
Since aging muscles display mitochondrial dysfunction 
[25], we assessed the expression levels of mitochondria 
and oxidative metabolism markers such as mitochondrial 
transcription factor A (TFAM), ATP-synthase β-subunit 
(β-ATPase), SDH subunit-A (SDHA), peroxisome 
proliferator-activated receptor gamma (PPARγ), and 
PPARγ-coactivator-1-alpha (PGC1α). In line with the 
results reported in Figure 5A, we observed an up-
regulation of SDHA in old Tg mice compared to WT 
(Figure 5B). In addition, old Tg mice showed an 
increase in PPARγ. On the other hand, β-ATPase and 
PGC1α, a master regulator of mitochondrial biogenesis, 
did not show different expression levels among the three 
genotypes. Yet, Ghrl KO mice showed an up-regulation 
of TFAM, another marker of mitochondrial biogenesis. 
Coherently, the mitochondrial content in muscles, 
assessed as the quantity of cytochrome c oxidase subunit 
4 (COX4) in immunofluorescence, was higher in Ghrl 
KO mice than in WT, both in young and old animals 
(Figure 5C). Of note, also old Tg animals had 




Figure 3. Muscle functionality and behavior in young and old WT, Tg, and Ghrl KO mice. (A) Average score trend in hanging 
wire test of 3-month old (young) and 24-month old (old) WT, Tg, and Ghrl KO mice and (B) average holding impulse in the same test. 
Young mice: WT = 21, Tg = 21, Ghrl KO = 27; old mice: WT = 9, Tg = 16, Ghrl KO = 7. *p<0.05 and **p<0.01 vs WT. (C) Memory was 
evaluated through the object recognition test and expressed as a discrimination index between a familiar and a novel object (seconds 
on novel – seconds on familiar)/(seconds on novel + seconds on familiar). (D) Anxiety was assessed as the time spent immobile during 6 
minutes of tail suspension. Young mice: WT = 5, Tg = 5, Ghrl KO = 6; old mice: WT = 6, Tg = 7, Ghrl KO = 6. For each box plot, the lower 
and up boundaries denote the 25th and the 75th percentile of each data set, respectively, the horizontal line represents the median, 
and the whiskers represent the min and max of values. *p<0.05 and **p<0.01 old vs. young; $p<0.05 and $$p<0.01 Tg and Ghrl  
KO vs. WT. 
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Inflammation markers in old WT, Tg, and Ghrl KO 
mice 
 
With age, the spleen undergoes enlargement and 
disorganization of its architecture that can lead to age-
related decline of immune function and chronic 
inflammation, that, in turn, could contribute to the 
decrease in muscle mass and functionality [26–28]. All 
three genotypes showed a significant increase of spleen 
weight with age, although to a lesser extent in Ghrl KO 
mice (Table 1). Adipose tissue as well contributes to the 
establishment of age-associated systemic inflammation, 
as it becomes dysfunctional with age, increasing  
the production of pro-inflammatory cytokines while 
decreasing the anti-inflammatory ones [29]. TNFα 
mRNA levels in epididymal fat increased during aging in 
all the genotypes, but to a lesser extent in Tg and Ghrl 
KO mice (Figure 6A), confirming the low-grade systemic 
inflammation in these mice. The impact of ghrelin 
peptide levels on age-related systemic inflammation was 
explored through an antibody-spotted array directed 
against several circulating markers of inflammation on 
pooled samples (Figure 6B and Supplementary Figure 2). 
As expected, old WT mice showed a general tendency to 
increase pro-inflammatory markers and to decrease the 




Figure 4. Ghrelin peptides effects on sarcopenia-dependent atrophy. (A) Atrogin-1 (Fbxo32) expression in gastrocnemius (GAS) and 
tibialis anterior (TA) of 3-month old (young) and 24-month old (old) mice determined by real-time RT-PCR. In GAS, young mice: WT = 4, Tg = 
4, Ghrl KO = 4; old mice: WT = 4, Tg = 3, Ghrl KO = 4. In TA, young mice: WT = 4, Tg = 3, Ghrl KO = 4; old mice: WT = 8, Tg = 6, Ghrl KO = 5.  
(B) Cathepsin-L (Ctsl), (C) Bnip-3 (Bnip3), and (D) IGF-1 (Igf1) expression in gastrocnemius of 3-month old (young) and 24-month old (old) mice 
determined by real-time RT-PCR. Young mice: WT = 3, Tg = 3, Ghrl KO = 4; old mice: WT = 7, Tg = 9, Ghrl KO = 5. (E) Cross-sectional area (CSA) 
frequency distribution of myofibers in GAS of old WT, Tg, and Ghrl KO mice. WT= 4, Tg= 3, Ghrl KO= 5. The shadowed area of the graph 
represents the section of statistically significant differences among curves. Data are presented as mean ± SEM. *p<0.05 and **p<0.01 old vs. 
young; $p<0.05 and $$p<0.01 Tg and Ghrl KO vs. WT. 
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Figure 5. Metabolic shift in TA muscles of WT, Tg, and Ghrl KO mice. (A) Representative images of succinate dehydrogenase (SDH) 
staining (scale bars: 200 μm) representing the oxidative capacity of TA muscles of 3-month old (young) and 24-month old (old) mice and 
quantification of SDH-positive fibers in TA muscle presented as the percentage of SDH-positive area above the total muscle surface. Young 
mice: WT= 5, Tg= 4, Ghrl KO= 5; old mice: WT= 4, Tg= 3, Ghrl KO= 5. (B) Representative Western blots images and protein densitometry 
quantification for mitochondrial transcription factor A (TFAM), ATP-synthase β-subunit (β-ATPase), succinate-dehydrogenase complex 
subunit-A (SDHA), peroxisome proliferator-activated receptor gamma (PPARγ), and PPARγ-coactivator-1-α (PGC1α) protein levels. Protein 
levels were probed in gastrocnemii of old mice, WT= 4, Tg= 5, Ghrl KO= 5. (C) Representative images of cytochrome c oxidase subunit 4 
(COX4) immunofluorescence (scale bars: 200 μm) and quantification. Young mice: WT = 3, Tg = 3, Ghrl KO = 3; old mice: WT = 4, Tg = 4, Ghrl 
KO = 4. Data are presented as mean ± SEM. *p<0.05 and **p<0.01, old vs. young; $p<0.05 and $$p<0.01, Tg and Ghrl KO vs. WT. 
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(reference line in Figure 6B). By contrast, a trend towards 
reduction could be observed in both old Tg and Ghrl 
KO mice compared to old WT for some pro-
inflammatory markers, such as SDF1α, eotaxin-1 
(CCL11), I-309 (CCL1), leptin, M-CSF, and IL-12p70, 
seemed to be lower. Conversely, the anti-inflammatory 
soluble TNF-R1 gave the impression of being increased 




Figure 6. Inflammatory response in old WT, Tg, and Ghrl KO mice. (A) TNF-α (Tnf) expression in epididymal fat of 3-month old 
(young) and 24-month old (old) WT, Tg, and Ghrl KO mice, determined by real-time RT-PCR. Data in bar graph are presented as mean ± SEM. 
Young mice: WT= 3, Tg= 4, Ghrl KO = 4; old mice: WT= 5, Tg= 7, Ghrl KO = 5. (B) Serum biomarkers involved in systemic inflammation 
normalized on the levels in young WT mice (reference line). Young mice WT=4; old mice: WT= 4, Tg= 4, Ghrl KO = 4 pulled into two groups. 
Data in bar graph are presented as mean ± SD. *p<0.05 and **p<0.01, old vs. young; $p<0.05 Tg and Ghrl KO vs. WT. 
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UnAG pharmacological treatment improved the 
physical performance of old WT mice by inducing a 
metabolic switch in muscles 
 
Old WT mice were treated with UnAG (100 μg/kg 
intraperitoneally once a day) for 28 days and compared 
to age- and weight-matched controls treated with saline. 
UnAG administration had no significant effect on total 
body weight (Figure 7A), daily food intake (Figure 7B), 
and epidydimal fat (Figure 7C). On the other hand, 
muscle weights showed a tendency towards higher 
values in UnAG-treated mice that were significant in 
gastrocnemii, quadriceps, an d EDL muscles (Figure 
7D). UnAG progressively increased the physical 
performance of mice, seen as “falls and reach” score 
and holding impulse in the hanging wire test (Figure 7E, 
7F). The difference in the holding impulse in UnAG-
treated mice reached statistical significance at 28 days. 
However, at the end of the experimental period, there 
was no shift towards larger cross-sectional areas of 
gastrocnemius fibers, although the shape of UnAG-
treated muscle distribution showed an increment of 
middle-sized fibers (Figure 7G). Despite the increase in 
muscle weight (Figure 7D), UnAG did not alter the 
expression of IGF-1 (Figure 7H). Furthermore, UnAG 
treatment was unable to decrease the expression of 
Atrogin-1 and cathepsin-L (Figure 7I, 7J). Since the 
better muscle performance could derive from a shift in 
muscle metabolism, we assessed SDH activity in 
gastrocnemii and observed that, indeed, UnAG induced 





The decline in muscle mass, functionality, and physical 
performance distinctive of aging can be ascribed, at 
least in part, to age-associated endocrine and metabolic 
dysfunction. Among the dysregulated hormones, in 
humans, it has been observed reduced circulating levels 
of ghrelin and decreased expression on the cell surface 
of its receptor GHSR-1a [17] that may contribute to 
sarcopenia by facilitating the progression of muscle 
atrophy and limiting skeletal muscle regeneration 
capability. No changes were reported for UnAG in 
elderly compared to young people [30], although the 
broad age range (21-65 years) of the “young” group 
could have leveled any difference. In mice, on the 
contrary, it was reported an increase in circulating 
levels of AG during aging and no changes in UnAG 
[16]. However, together with the age-related increase of 
AG, we also observed a rise in the circulating levels of 
UnAG (Figure 1A, 1B), possibly owing to the different 
methods used compared to the previous work. The 
increase of UnAG could represent a compensatory 
mechanism to a decline in receptor or post-receptor 
functions, as previously suggested for AG [17]. 
However, the undetectable levels of Ghsr in skeletal 
muscles and the absence of a known receptor for UnAG 
prevented us from demonstrating such a hypothesis in 
this specific context. Still, the age-related increase in 
AG and UnAG levels may be part of an adaptive 
response to a negative energy balance and suggests that 
these peptides could be involved in the aging process 
for the many activities that characterize each or both 
forms of ghrelin peptide, including the protection from 
muscle wasting (AG and UnAG; [7]). Muscle atrophy is 
indeed one of the main degenerative processes involved 
in sarcopenia and, for the above-mentioned anti-
atrophic activity of AG and UnAG, it was reasonable to 
expect that high circulating levels of UnAG, as in the 
Tg mice used in this study, would result in less 
sarcopenia by protecting from muscle wasting. This was 
actually the case, being Tg muscles partially resistant to 
atrophy during aging (Figure 4A, 4E). 
 
On the contrary, the finding that old Ghrl KO mice 
were atrophy-resistant, featuring enhanced physical 
performance (Figure 3A, 3B), lower levels of 
catabolism-related genes (Figure 4A–4C), and larger 
myofiber areas than WT mice (Figure 4E), was less 
expected, as we have formerly demonstrated that, upon 
a traumatic event, muscle regeneration in Ghrl KO mice 
is reduced, due to an impaired satellite cell self-renewal 
activity [22]. Also, old Ghrl KO mice are more 
susceptible to fasting-induced muscle atrophy likely 
because of an altered mitochondrial function [9]. 
Nevertheless, most of our findings on aged Ghrl KO 
mice are in accordance with the previous demonstration 
that ghrelin gene deletion results in the prevention of 
the age-associated decline in muscle strength and 
endurance [18]. Yet, we also obtained some different 
results compared with the previously published ones. 
For a start, we observed an increase in body weight with 
aging in both WT and Ghrl KO mice (Figure 2A and 
Table 1), without differences in old Ghrl KO compared 
to old WT. However, this divergence could arise from 
the different caging conditions used, as individually-
housed animals eat more and move less than animal 
housed in groups, thus leading, in the long run, to 
significant body weight differences. More strikingly, 
although 24-month-old mice are significantly heavier 
than 3-month-old animals, comparing 24-month-old 
with intermediate ages (6- and 12-month-old mice), we 
could observe a drop in body weight in both genotypes. 
 
The similar loss of muscle weight in WT and Ghrl KO 
during aging suggested that ghrelin deletion could have 
no effects on muscle mass. However, a more accurate 
assessment of muscles uncovered relevant differences 
between WT and Ghrl KO mice. The lack of ghrelin 
affected muscle cross-sectional areas, with old Ghrl KO  
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Figure 7. Exogenous administration of UnAG in old WT mice attenuates age-related muscle decline. UnAG 100 μg/Kg was 
injected daily i.p. for 28 days to 18-month-old mice (N = 6). Age- and weight-matched controls were injected with saline (N =6). (A) Total body 
weight; (B) daily food intake; (C) change in epidydimal fat mass normalized to nose-to-anus length (NAL) and in (D) muscle mass normalized 
to the tibial length (TL). GAS: gastrocnemius, SOL: soleus, QUAD: quadriceps, TA: tibialis anterior, EDL: extensor digitorum longus. (E) Average 
score trend in hanging wire test and (F) average holding impulse. (G) Cross-sectional area (CSA) frequency distribution of myofibers in GAS. 
The shadowed areas of the graph represent the sections of statistically significant differences among curves. (H) IGF-1 (Igf1), (I) Atrogin-1 
(Fbxo32), and (J) Cathepsin-L (Ctsl) expression in gastrocnemius determined by real-time RT-PCR. (K) Quantification of SDH staining in TA 
muscle presented as the percentage of SDH-positive area above the total muscle surface. Data in bar graph are presented as mean ± SEM. 
For box plots, the lower and up boundaries denote the 25th and the 75th percentile of each data set, respectively, the horizontal line 
represents the median, and the whiskers represent the min and max of values. *p<0.05 and **p<0.01 vs. saline-treated controls. 
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muscles displaying a reduced number of the smallest 
myofibers in CSA distribution (Figure 4E) and 
generally a reduced induction of markers of protein 
catabolism compared to WT animals (Figure 4A–4C). 
Of note, the expression of Atrogin-1 was lower also in 
young Ghrl KO mice than in WT littermates (Figure 
4A). The protection from age-induced muscle atrophy 
apparently does not depend on the modulation of IGF-1 
that in old Ghrl KO mice is even lower than in WT 
(Figure 4D). On the contrary, the preservation of Ghrl 
KO muscles may partially be due to an increased 
mitochondrial content in Ghrl KO, as suggested by the 
increased levels of TFAM and COX4 (Figure 5B, 5C). 
 
The changes in muscle mass occurring during aging 
may arise from the age-related dysregulation of the 
immune system that leads to progressive systemic 
inflammation, with a general increase in circulating pro-
inflammatory cytokines, which can affect muscle 
homeostasis. Actually, old WT mice exhibited higher 
spleen dimension, increased levels of TNF-α expression 
in epidydimal adipose tissue, and a general tendency of 
augmented plasmatic pro-inflammatory markers 
compared to young animals, suggesting the existence of 
low-grade systemic inflammation (Table 1 and Figure 
6A, 6B). Based on the vast amount of the anti-
inflammatory activities of ghrelin peptides [31], a 
worsening of the inflammatory status in Ghrl KO mice 
was plausible. However, in Ghrl KO mice a trend 
towards reduced inflammation could be observed, both 
in the adipose tissue and in the circulation (Figure 6A, 
6B). Such a phenotype closely resembles that of Ghsr 
KO mice [32], where the ablation of AG receptor 
promotes an anti-inflammatory (M2) macrophages shift, 
reduced macrophage infiltration, and decreased pro-
inflammatory cytokine expression in both white and 
brown adipose tissues. Also, the pro-inflammatory 
effects of Ghsr-1a on macrophages profoundly limits 
lipid mobilization and energy expenditure in adipose 
tissue [21], processes that are highly perturbed during 
aging [33]. In particular, it was proposed that AG could 
participate in the age-related impairment of 
thermogenesis –thus contributing to the onset of age-
related obesity and insulin resistance– through its 
receptor Ghsr-1a, whose expression in fat increases with 
aging [32]. Altogether, these observations strongly 
suggest that, in Ghrl KO mice, one of the major 
determinant factors of their overall better condition is 
the lack of AG-mediated activation of Ghsr-1a. 
Conversely, the lack of UnAG in these mice becomes 
critical under stressful conditions, such as starvation or 
acute muscle injury, impacting on the physiological 
homeostasis [9, 22]. 
 
Of note, the feeding behavior of Ghrl KO mice was 
different from what previously reported [18, 34], as we 
observed higher food consumption in young Ghrl KO 
mice (Table 1). 
 
Besides the effects on skeletal muscle, aging also 
associates often with a gradual cognitive impairment 
and depression that deeply worst elder people quality of 
life [35]. The role of AG in regulating sleep and 
memory [36] and its anti-depressant activity when 
administered to stressed mice [37] suggest that the 
impairment of ghrelin signaling during aging could 
affect cognitive function as well. In assessing the 
behavioral contribution to the physical performance 
tests, we skimmed the surface of this issue and 
surprisingly found that the lack of ghrelin peptides 
improved the memory capacity of young mice, although 
this effect was not maintained during aging (Figure 3C). 
Conversely, the lack of the ghrelin gene protected 
against the onset of the aging-dependent depression-like 
behaviors (Figure 3D). Altogether, the pattern of 
cognitive function could have partially affected the 
measure of endurance in the hanging wire test (Figure 
3A, 3B), as the cleverness could drive the mice to 
quickly reach the ends of the wire (Figure 3C), while 
the anxiety/depression (Figure 3D) may induce the  
mice to abandon the attempt. Therefore, old WT mice 
could have performed worse than their young 
counterpart also because of the establishment of age-
induced anxiety/depression. On the contrary, Ghrl KO 
mice could have had a starting advantage due to higher 
cognitive performance in youth. Although this 
parameter declined with age, it reached the level of 
young WT animals, and the lack of anxiety/depression 
during aging could have resulted in overall better 
performances both in young and old Ghrl KO mice than 
their WT peers. 
 
Exogenous administration of AG to overcome a 
presumed peripherical ghrelin resistance has been 
explored in several contexts characterized by loss of 
skeletal muscle mass, including cancer cachexia [38, 
39] and aging [18]. However, while in cancer cachexia 
the administration of AG has a beneficial activity on 
skeletal muscle also by contrasting anorexia and the 
rapid loss of adipose tissue, in sarcopenia the effects on 
skeletal muscle are limited and accompanied by an 
increase in adiposity that might worsen age-related 
insulin resistance and metabolic dysfunction. The pro-
adipogenic feature of AG relies on its acylation and 
resulting binding to Ghsr-1a [6, 40]. Since UnAG does 
not activate this receptor and does not increase fat mass, 
while protecting the skeletal muscle from several 
atrophic stimuli [41], we investigated the potentiality of 
this hormone in preventing sarcopenia by monitoring 
the aging of Myh6/Ghrl Tg mice characterized by 
normal levels of AG but increased levels of UnAG [7, 
13]. Despite both Tg and WT animals display similar 
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tendencies in how total body weight, epididymal fat, 
and skeletal muscle mass change with aging (Figure 2 
and Table 1), higher circulating levels of UnAG seem to 
globally maintain in the long run the structure, 
performance, and metabolism typical of young muscles 
(Figure 3A, 3B, Figures 4, 5), despite a reduction with 
aging of Igf1 expression in muscles (Figure 4D). In 
particular, old Tg muscles display higher levels of 
mitochondrial proteins than WT littermates (Figure 5B) 
that likely accounts for the maintenance of the oxidative 
metabolism (Figure 5A) and the overall protection from 
sarcopenia. This is consistent with the ability of UnAG 
to impair muscle catabolism by mitigating 
mitochondrial damage [14]. The preserved muscle mass 
and functionality may be the result of the direct anti-
atrophic activity of UnAG [7, 8], as well as of the 
seeming reduced age-associated chronic inflammation 
(Figure 6B). Although old Tg spleen weight did not 
differ from that of WT (Table 1), old Tg animals 
showed a tendency towards lower levels of 
inflammatory markers (Figure 6B), such as SDF-1α, I-
309, leptin, M-CSF, IL-12p70, and higher levels of 
soluble TNF-R1 that can act as scavenger for the 
circulating inflammatory TNF-α[42]. On the other 
hand, age-associated IL-12 and IL-13 levels were quite 
similar to those observed in WT animals, possibly 
reflecting the presence of AG in Tg mice. 
 
To sum up, we showed that both high circulating levels 
of UnAG and the lack of ghrelin gene prevent the 
decline of muscle function associated with aging, 
although with different dynamics. Indeed, old Tg mice 
seem to preserve the characteristics of young animals, 
while Ghrl KO mice features deteriorate with aging. 
However, young Ghrl KO mice in general show more 
favorable traits compared to WT animals that result, on 
the whole, in better performances in aged Ghrl KO 
animals. The only exception is the SDH activity (Figure 
5A) that declines with age in both WT and Ghrl KO 
mice, but, differently from the other parameters 
assessed in this work, young Ghrl KO mice do not have 
the initial advantage of higher SDH activity in youth. 
On the contrary, similarly to other parameters, Tg mice 
maintain a constant SDH activity, putatively due to 
higher levels of mitochondrial proteins (Figure 5B, 5C). 
Therefore, we can hypothesize that the maintenance of 
the oxidative metabolism could, at least in part, explain 
the protection from sarcopenia in Tg mice, while, in 
Ghrl KO mice, the lack of Ghsr-1a-mediated 
inflammation could play a major role. The fact that Ghrl 
KO mice are protected from sarcopenia might still 
appear in contradiction with our previous work 
demonstrating that both AG and UnAG have anti-
atrophic activities [7]. However, it should be noted that 
the anti-atrophic effects of AG and UnAG were 
assessed in Ghsr KO mice, i.e., in circumstances in 
which AG was not signaling via Ghsr-1a, but through a 
yet unidentified receptor. 
 
The astonishingly similarity between old Ghrl KO mice 
and old Ghsr KO mice indeed strongly suggests a 
detrimental role for GHSR-1a in the onset of 
sarcopenia. We reckon that, in mice, the physiological 
increase of UnAG with aging is not enough to 
counteract the adverse effects of the increased AG 
levels. To test this hypothesis, we administered 
pharmacological doses of UnAG to aging (18-month-
old) WT mice for 4 weeks and assessed the effects on 
muscle mass and performance. As expected, UnAG, 
which does not signal through Ghsr-1a, did not induce 
changes in body weight, food intake, and adiposity 
(Figure 7A–7C). UnAG-treated mice showed higher 
gastrocnemii and quadriceps muscle weights (Figure 
7D) that likely reflect protection from the sharp 
reduction in muscle mass observed between middle-
aged and old mice (Figure 2C and Table 1), rather than 
induction of hypertrophy. Accordingly, UnAG 
treatment did not induce changes in Igf1 expression 
(Figure 7H). UnAG was able to gradually improve the 
physical performances of treated mice (Figure 7E, 7F). 
Remarkably, the higher muscle mass and the better 
physical performances were not accompanied by a 
reduction in the expression of genes associated with 
protein catabolism (Figure 7I, 7J), nor by a shift 
towards larger fiber areas in muscle sections (Figure 
7G). Paradoxically, the CSA distribution showed even a 
reduction in the frequency of larger fibers in UnAG-
treated mice. However, this did not reflect an atrophic 
status, since there was not an overall shift towards 
smaller CSA but a rise in the portion of middle-sized 
fibers. We postulate that this increase in middle-sized 
fibers could reflect the UnAG-induced shift towards 
oxidative metabolism (Figure 7K) that is usually 
characterized by fibers with reduced areas compared to 
the glycolytic ones. 
 
Altogether, these results suggest that, in humans, the 
adverse effects of impaired ghrelin signaling in aging 
could be mainly due to the decline in UnAG rather than 
AG and should encourage the design of analogs to 
UnAG rather than AG to therapeutically treat 
sarcopenia. 
 
MATERIALS AND METHODS 
 
Animals and treatments 
 
Animal experiments were performed according to 
procedures approved by the Institutional Animal Care 
and Use Committee at the University of Piemonte 
Orientale. C57BL/6 male mice, matched for age and 
weight, were used for all experiments. C57BL/6 Ghrl-/- 
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(Ghrl KO) and C57BL/6-Myh6/Ghrl transgenic (Tg) 
mice were generated as previously described [7, 22, 43]. 
WT mice were littermates of Tg animals. Ghrl KO 
strain was kept in homozygosity. Animals were housed 
in groups of 4/6 animals and fed ad libitum with 
unrestricted access to drinking water. For food intake 
analysis and behavioral tests, mice were single-caged 
for the acclimation plus experimental periods. The 
light/dark cycle in the room consisted of 12/12 h with 
artificial light. The numbers of mice ranged from 4 to 
27 per experiment. BMI was calculated as animal 
weight/(nose-to-anus length)2. AG and UnAG plasmatic 
levels were measured by EIA kits (SPIbio Bertin 
Pharma). In the experiments with i.p. injections of 100 
μg/Kg UnAG (PolyPeptide Laboratories; Strasbourg, 
France), controls were age- and weight-matched saline-
injected animals. Mice were killed through cervical 
dislocation, and tissues used for the study immediately 
excised, weighted, and processed or stored for further 
analysis. 
 
Hanging wire test 
 
A wire-hanging test was employed to assess whole-
body muscle strength and endurance. The test was 
performed as previously described [13]. Briefly, mice 
were subjected to 180 sec hanging test, during which 
“falling” and “reaching” scores were recorded. When a 
mouse fell or reached one of the sides of the wire, the 
“falling” score or “reaching” score was diminished or 
increased by 1, respectively. A Kaplan-Meier-like curve 
was created afterward. Moreover, the longest time 
between two falls was taken as the latency-to-fall value 
and used to calculate the holding Impulse (i.e., the 
hanging time x body mass). 
 
Object recognition test 
 
Recognition memory was measured using various 
objects of different sizes and materials, as previously 
described [44]. Briefly, mice were separated in single 
cages 10 days before the test. The task started with a 
familiarization trial (day 1) in which two identical 
objects were presented to the animals, followed by the 
test trial (day 2), where one familiar object was 
substituted with a novel one. In detail, in day 1, mice 
were left with two identical objects (familiarization 
phase). Exploration was recorded for 10 min by an 
investigator blinded to the strain assessed. Sniffing, 
touching, and stretching the head toward the object at a 
distance  2 cm were scored as object investigation. In 
day 2 mice were again left in the same cage containing 
two objects: one identical to one of the objects 
presented during the familiarization phase (familiar 
object), and a new, different one (novel object), and the 
time spent exploring the two objects was recorded for 
10 min. Memory was expressed as a discrimination 
index calculated as follows: (seconds on novel–seconds 
on familiar)/(seconds on novel + seconds on familiar). 
Animals with memory impairment spend lesser 
investigating time with the novel object, thus giving a 
lower discrimination index. 
 
Tail suspension test 
 
Mice anxiety/depression was measured as previously 
described [45]. Briefly, mice were individually 
suspended in the air by tape attached to a shelf (50 cm 
height) for 6 min. Trials were video-recorded, and a 
blinded experimenter scored the time during which 
mice remained immobile as a measure of depressive-
like behavior. A small cylindrical tube was slipped over 





Muscles were excised, weighted, mounted in Killik 
embedding medium (Bio-optica), frozen in liquid-
nitrogen-cooled isopentane, and stored at -80 °C. 
Transverse muscle sections (7 µm) were cryosectioned 
from the middle part of each muscle. Myofiber areas 
were determined by immunofluorescence with anti-
laminin (1:200; Dako). Slices were fixed in 4% PFA for 
20 min, washed, permeabilized with 0.2% Triton X-100 
in 1% BSA for 15 min, and blocked with 4% BSA for 
30 min. One hour of incubation with primary antibodies 
was followed by 45 min of secondary antibody (Alexa 
Fluor 488-anti-rabbit; Thermo Fisher Scientific) at RT. 
DAPI was incubated for 5 min at RT to visualize nuclei. 
SDH staining was performed to reveal the oxidative 
fibers within a muscle. Frozen transverse TA muscles 
were incubated in a working solution (SUCCINIC 
DEHYDROGENASE Stain Lyophilized, Bio-optica) 
for 45 minutes at 37°C. The sections were then rinsed in 
distilled water, fixed in 4% PFA for 10 minutes, placed 
in 15% ethanol for 10 minutes, and, finally, mounted 
with aqueous mounting medium. Images of whole 
muscle sections were acquired with the slide scanner 
Pannoramic Midi 1.14 (3D Histech) and cross-sectional 
areas (CSA) of fibers or SDH staining quantified with 




Tissue sections were fixed in 4% PFA for 10 minutes, 
washed in PBS, permeabilized with 1% BSA 0,2% 
triton x-100 for 20 minutes. For blocking the unspecific 
binding sites, slices were incubated in 4% bovine serum 
albumin (BSA) for 2 hours at RT and then sections  
were stained with an anti-COX4 antibody (1:250;  
Cell Signaling technology, Danvers, MA, USA) or  
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with an anti-laminin antibody (1:200; Dako, Agilent 
Technologies, Santa Clara, CA). After washing, 
sections were incubated with the appropriate Alexa 
Fluor Dyes-conjugated secondary antibody (488-anti-
rabbit; Thermo Fisher Scientific) for 1 hour at RT. 40,6-
diamidino-2-phenylindole (DAPI) was incubated for 5 
minutes to visualize nuclei. 
 
Images were acquired using the slide scanner 
Pannoramic Midi Scanner 1.14 (3D Histech) and 
quantified with ImageJ v1.49o software. 
 
Gene expression analysis 
 
Total RNA from muscles was extracted by RNAzol 
(Sigma-Aldrich). RNA was retro-transcribed with High-
Capacity cDNA Reverse Transcription Kit (Thermo 
Fisher Scientific), and real-time PCR was performed 
with the StepOnePlus Real-Time PCR System (Thermo 
Fisher Scientific) using the following TaqMan assays: 
Mm00499518_m1 (Fbxo32, Atrogin-1/MAFbx), Mm00 
439560_m1 (Igf1), (Mm00515597_m1 (Ctsl), Mm012 
08835_m1 (Ppargc1a), Mm00616415_m1 (Ghsr), 





Tissue samples from gastrocnemii were homogenized 
by using GentleMACS Dissociator (Miltenyi Biotec) 
and lysed in ice-cold RIPA Buffer (50 mM Tris/HCL, 
pH= 8.0; 1% Triton X-100; 150mM NaCl; 0.5% sodium 
deoxycholate; 0.1% SDS) supplemented with a protease 
inhibitor cocktail (Roche) and a phosphatase inhibitor 
cocktail (Sigma-Aldrich). A clear supernatant was 
obtained by centrifugation of lysates at 13,000 g for 20 
min at 4°C. Protein concentration in the supernatant was 
determined by Bradford protein assay (Bio-Rad). 
Aliquots of total cell lysates (20 μg) were then separated 
by SDS-PAGE by using Miniprotean precast gels 
(BioRad), and proteins were transferred to 
nitrocellulose membranes (BioRad). 
 
Membranes were blocked 1h at RT with 5% non-fat 
milk in Tris-buffered saline with 0.05% Tween 20 and 
then probed by using the following antibodies directed 
against PGC1α (AB3242; Millipore), β chain-ATP 
Synthase (MAB3494; Millipore), PPARγ (sc-7273; 
Santa Cruz Biotechnology), SDH (sc-377302; Santa 
Cruz Biotechnology), TFAM (sc-23588; Santa Cruz 
Biotechnology), GAPDH (G8795; Sigma-Aldrich). 
 
The appropriate secondary horseradish peroxidase-
conjugated antibodies from Jackson Immunoresearch 
were used in 5% not-fat- milk (blocking solution) for 1 
h at room temperature. Immunoreactive bands were 
visualized by Clarity Western ECL Substrate (Biorad). 
Equal loading of samples was confirmed by GAPDH 
(G8795; Sigma-Aldrich) normalized and quantified by 
densitometry by ImageJ Software. 
 
Mouse inflammation antibody array 
 
Serum cytokines and biomarkers of systemic 
inflammation were detected using the Mouse 
Inflammation Antibody Array C1 (RayBiotech, 





All data were expressed as mean ± SEM or mean ± SD, 
when appropriate, absolute values, or percentages. 
Outliers in the measurements were identified by mean 
of the interquartile range (IQR), as either below Q1 – 
1.5 IQR or above Q3 + 1.5 IQR, and excluded from the 
analysis. The variation between groups was compared 
by using nonparametric Wilcoxon, Mann-Whitney U, 
Friedman, or χ2 tests, as appropriate. Statistical 
significance was assumed for p<0.05. The statistical 
analysis was performed with IBM SPSS Statistics for 
Windows version 25.0. The * symbol indicates a 
statistically significant difference between old and 
young animals, for any genotype group; the § symbol 
identifies a statistically significant difference between 





AG: acylated ghrelin; β-ATPase: ATP-synthase beta-
subunit; BLC: B lymphocyte chemoattractant 
(CXCL13); BMI: body mass index; BSA: bovine serum 
albumin; CCL11: C-C motif chemokine ligand 11 
(eotaxin-1); CCL1: C-C motif chemokine ligand 1 (I-
309); COX4: cytochrome c oxidase subunit 4; CSA: 
cross-sectional area; CXCL13: C-X-C motif chemokine 
ligand 13 (BLC); DAPI: 4′,6-diamidino-2-phenylindole; 
EDL: extensor digitorum longus; Fbxo32: F-Box 
Protein 32 (Atrogin-1); GAPDH: glyceraldehyde 3-
phosphate dehydrogenase; GAS: gastrocnemius; GH: 
growth hormone; Ghrl: ghrelin (gene); Ghsr: growth 
hormone secretagogue receptor (gene); GHSR-1a: 
growth hormone secretagogue receptor type 1a; IL-13: 
interleukin-13; IL-12: interleukin-12; IL-12p70: 
interleukin-12 70 kDa light chain; KO: knock-out; M-
CSF: macrophage colony-stimulating factor; Myh6: 
myosin heavy chain 6 (gene); PGC1α: PPARγ-
coactivator-1-alpha; PBS: Phosphate Buffered Saline; 
PFA: paraformaldehyde; PPARγ: peroxisome 
proliferator-activated receptor gamma; Ppif: peptidyl-
prolyl cis-trans isomerase, mitochondrial; QUAD: 
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quadriceps; SDF1α: stromal cell-derived factor-1-alpha; 
SDH: succinate dehydrogenase; SDHA: succinate 
dehydrogenase complex flavoprotein subunit A; SOL: 
soleus; TA: tibialis anterior; TFAM: mitochondrial 
transcription factor A; TNFα: tumor necrosis factor 
alpha; TNF-R1: tumor necrosis factor receptor 1; Tg: 
transgenic; UCP1: Uncoupling Protein 1; UnAG: 
unacylated ghrelin; WT: wild type. 
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Supplementary Figure 1. Aging-induced atrophy in WT muscles. Cross-sectional area (CSA) frequency distribution of myofibers in GAS 
of young (N=2) and old (N=4) WT mice. The shadowed area of the graph represents the section of statistically significant differences among 




Supplementary Figure 2. Array map of the Mouse Inflammation Antibody Array. Each antibody is spotted in duplicate vertically. 
